Related references
Note: Only part of the references are listed.Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer
Masaki Shiota et al.
INTERNATIONAL JOURNAL OF UROLOGY (2019)
Current treatment strategies for advanced prostate cancer
Kazumasa Komura et al.
INTERNATIONAL JOURNAL OF UROLOGY (2018)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E. Kyriakopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Gene Polymorphism-related Individual and Interracial Differences in the Outcomes of Androgen Deprivation Therapy for Prostate Cancer
Naohiro Fujimoto et al.
CLINICAL GENITOURINARY CANCER (2017)
Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer
Masaki Shiota et al.
INTERNATIONAL JOURNAL OF UROLOGY (2016)
Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7
Masaki Shiota et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7
Masaki Shiota et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability
Hiroaki Matsumoto et al.
CANCER RESEARCH (2013)
Mutual Regulation between Raf/MEK/ERK Signaling and Y-Box-Binding Protein-1 Promotes Prostate Cancer Progression
Kenjiro Imada et al.
CLINICAL CANCER RESEARCH (2013)
Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression
Masaki Shiota et al.
ENDOCRINE-RELATED CANCER (2011)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
YB-11s upregulated during prostate cancer tumor progression and increases P-glycoprotein activity
P Giménez-Bonafé et al.
PROSTATE (2004)
The pleiotropic functions of the Y-box-binding protein, YB-1
K Kohno et al.
BIOESSAYS (2003)
Share Paper
